Mediation Bid Postpones First Yaz, Yasmin Lawsuit TrialJan 5, 2012 | Parker Waichman LLP
The much anticipated first bellwether trial in the Yaz and Yasmin multidistrict litigation won't be starting next week after all. The trial was postponed, and U.S. District Court Judge David Herndon has ordered both sides to meet with a mediator to discuss possible settlement of Yaz and Yasmin lawsuits.
George Washington law professor Stephen Saltzburg has been appointed special master in the litigation. In an order dated December 31, Judge Herndon directed attorneys for both plaintiffs and defendants to meet with Saltzburg “without delay” to negotiate in good faith. According to FiercePharma, Saltzburg previously handled mediation for more than 20,000 Seroquel product liability lawsuits.
More than 10,000 lawsuits are pending before Judge Herndon in the Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100) in the U.S. District Court for the Southern District of Illinois. The lawsuits claim Yaz, Yasmin and similar drugs caused young women to suffer dangerous blood clots and other serious side effects.
Just last month, a panel of advisors for the U.S. Food & Drug Administration (FDA) recommended stronger label warnings for Yaz, Yasmin and similar oral contraceptives regarding their possible association with blood clots. The outside advisors voted 21-5 that current label warnings for Yaz, Yasmin and other pills made with the progestin, drospirenone, are inadequate and need to include clearer information about data that have linked the pills to a higher risk of blood clot